01Approach to the Critical Patient/attcp51

Encephalopathy and severe toxicity

›Critical presentation triggers

›Blood lead level (BLL) >= 70 micrograms per dL

›Immediate combination chelation required

›ICU level care

›Encephalopathy signs

›Delirium or altered consciousness

›Seizures

›Stupor or coma

›If seizures, benzodiazepines first line

›Lorazepam 0.1 mg/kg IV

›Diazepam 0.15 mg/kg IV as alternative

›Establish IV access before chelation

›Ensure adequate urine output before initiating

›Hold chelation if anuria or oliguria

Hemodynamic and airway priorities

›Initial stabilization targets

›Airway protection for GCS < 13

›Rapid sequence intubation preparation

›Avoid aspiration

›IV fluid resuscitation for hypoperfusion

›Normal saline bolus 20 ml/kg in children

›500 ml bolus in adults

›Blood pressure target MAP > 65 mmHg

›Hypertension common in chronic exposure

›Acute hypertensive emergency possible with encephalopathy

Monitoring and escalation triggers

›Monitoring bundle

02History/hx95

Presenting symptoms

›Core symptom cluster

›Abdominal pain

›Lead colic: severe intermittent crampy pain

›Constipation predominant rather than diarrhea

›Neuropsychiatric symptoms

›Headache and irritability

›Memory and concentration difficulties

›Mood changes and cognitive slowing

›Fatigue and malaise

›Pallor from anemia

›Weight loss in chronic exposure

›Neurological symptoms

›Peripheral neuropathy

›Wrist drop from radial nerve involvement

›Foot drop from peroneal nerve involvement

›Motor predominant over sensory

›Tremor and ataxia

›Cerebellar signs in severe cases

›Fine tremor of hands

Exposure history

›Environmental exposure sources

›Housing age

›Pre-1978 construction highest risk for lead paint

›Pre-1950 construction very high risk

›Water source

›Lead service lines or lead solder in plumbing

›Well water near industrial sites

›Occupational exposure

›Smelting and battery manufacturing or recycling

›Construction and painting trades

›Firing ranges

›Auto repair and radiator shops

›Non-occupational exposure sources

›Hobbies

›Stained glass work

›Bullet casting

›Pottery with lead glaze

›Traditional and herbal remedies

›Ayurvedic preparations

›Folk medicines imported from high-risk countries

›Kohl or surma cosmetics

›Food and substance sources

›Contaminated opium

›Imported spices with adulteration

›Lead-glazed pottery for food preparation

›Retained foreign bodies

›Bullet or shrapnel fragments

›Lead fishing sinkers ingested

›Timeline and onset context

›Acute versus chronic exposure pattern

›Recent renovation or hobby initiation

›Gradual insidious onset over months

›Recent immigration from high-exposure regions

›Prior residence in countries with high environmental lead burden

›Limited prior medical screening

Review of systems

›Gastrointestinal

›Metallic taste

›Pathognomonic historical clue

›Often overlooked in adults

›Nausea and vomiting

›Anorexia

›Progressive weight loss

›Renal and metabolic

›Polyuria

›Lead nephropathy contribution

›Fanconi-like syndrome in severe cases

›Gout symptoms

›Saturnine gout from lead nephropathy

›Joint pain and swelling

›Reproductive history

›Infertility concerns

›Male reduced sperm motility

›Female menstrual irregularity

›Pregnancy complications

›Miscarriage history

›Preterm birth

Past medical and family history

›Relevant past history

›Prior elevated blood lead levels or lead exposure episodes

›Previous chelation history

›Baseline BLL if known

›Pica history

›More common in children

›Reported in adults with lead-containing material ingestion

›Iron deficiency anemia

›Enhances intestinal lead absorption

›Concurrent finding common

›Hypertension

›Lead as contributing cardiovascular risk factor

›Chronic low-level exposure and cardiovascular mortality

›Family and household context

›Siblings and household contacts

›Screen all members if index case identified

›Take-home lead on occupational clothing

›Cultural practices in the household

›Traditional remedy use by family members

›Cooking vessel materials

03Physical Exam/exam68

Vitals and general appearance

›Vital sign findings

›Blood pressure

›Hypertension even at low-level chronic exposure

›Hypertensive urgency or emergency with encephalopathy

›Temperature

›Afebrile in pure lead poisoning

›Fever suggests concurrent infection

›Heart rate

›Tachycardia from anemia

›Bradycardia possible with severe conduction disturbance

›General appearance

›Pallor from anemia

›Microcytic appearance

›Conjunctival pallor

›Wasting

›Chronic exposure with anorexia

›Weight loss assessment

Head and neck exam

›Oral cavity

›Burton's lines

›Blue-black discoloration at gingival margin

›Classic but not always present

›More prominent with high BLL and poor oral hygiene

›Dentition

›Poor oral hygiene as exposure modulator

›Lead deposits at gingival margin enhanced by poor hygiene

›Fundoscopic exam

04Differential Diagnosis/ddx56

Life-threatening mimics

›Encephalopathy causes

›Encephalitis or meningitis

›ICD-10 G04.9 / G03.9

›Fever and meningismus help distinguish

›Status epilepticus from other causes

›ICD-10 G41.9

›Metabolic screen differentiates

›Hypertensive encephalopathy

›ICD-10 I67.4

›May coexist with lead poisoning

›Acute abdomen mimics

›Appendicitis

›ICD-10 K37

›Localized right lower quadrant tenderness distinguishes

›Bowel obstruction

›ICD-10 K56.7

›Imaging differentiates

›Renal colic

›ICD-10 N23

›Hematuria and flank pain distinguish

Hematologic differential

›Anemia differential

›Iron deficiency anemia

›ICD-10 D50.9

›No basophilic stippling

›Iron studies distinguish

›Sideroblastic anemia

05Laboratory Tests/lt64

Primary diagnostic test

›Blood lead level (BLL)

›Venous sample preferred over capillary

›Capillary screening acceptable as initial screen

›Confirm all capillary elevated results with venous draw

›BLL interpretation thresholds in children

›CDC reference value 3.5 micrograms per dL (updated 2021)

›3.5 to 9 micrograms per dL: mildly elevated, rescreening and education

›10 to 19 micrograms per dL: environmental assessment required

›20 to 44 micrograms per dL: environmental investigation and lead hazard control

›45 to 69 micrograms per dL: chelation therapy indicated

›>= 70 micrograms per dL: medical emergency, combination chelation

›BLL interpretation in adults

›< 5 micrograms per dL: normal

›5 to 10 micrograms per dL: follow-up required

›> 10 micrograms per dL: environmental assessment warranted

›>= 40 micrograms per dL symptomatic: chelation consideration

Hematologic studies

›Complete blood count with peripheral smear

›Anemia pattern

›Microcytic hypochromic anemia

›Hemoglobin may be < 7 mmol per L in severe cases

›Basophilic stippling of red blood cells

›Pathognomonic clue but not always present

›Aggregated ribosomes due to lead inhibition of pyrimidine 5 prime nucleotidase

›Reticulocytosis

›Hemolytic component

›Marker of active hemolysis

06Diagnostic Tests/dt70

Scoring Systems

›Severity stratification by BLL

›BLL-based action tiers

›Tier 1 (3.5 to 9 micrograms per dL children): education and rescreen

›Tier 2 (10 to 19): environmental investigation

›Tier 3 (20 to 44): environmental + hazard control

›Tier 4 (45 to 69): chelation therapy

›Tier 5 (>= 70): emergency combination chelation

›No validated severity score analogous to CURB-65 exists for lead poisoning

›Clinical judgment combined with BLL guides management

›Symptom severity modifies action thresholds

›Clinical severity classification

›Asymptomatic elevated BLL

›Environmental investigation is primary action

›Nutritional counseling and source removal

›Symptomatic lead poisoning

›Abdominal, neurological, or hematologic manifestations present

›Lower BLL threshold for chelation when symptomatic

›Lead encephalopathy

›Medical emergency regardless of exact BLL

›Combination chelation with BAL and CaNa2EDTA

MRI

›MRI brain indications

›Encephalopathy evaluation

›Subcortical white matter changes in severe cases

›Basal ganglia involvement possible

›Superior to CT for early white matter injury

›Pediatric neurodevelopmental assessment

07Disposition/dispo52

Admission indications

›ICU admission criteria

›BLL >= 70 micrograms per dL

›Combination chelation requiring intensive monitoring

›Renal function monitoring frequency

›Encephalopathy or seizures

›Neurological monitoring

›Airway protection risk

›Vasopressor or ventilatory support requirement

›Hemodynamic compromise

›Airway compromise

›General ward admission criteria

›BLL 45 to 69 micrograms per dL

›Oral chelation initiation with monitoring

›Mild to moderate symptoms

›Parenteral chelation required

›CaNa2EDTA IV or IM administration

›Monitoring for renal toxicity

›Inability to ensure removal from exposure source

›Ongoing home exposure without abatement plan

›Social or environmental barrier to safety

Discharge criteria

›Outpatient management criteria

›BLL < 45 micrograms per dL with no or mild symptoms

›Confirmatory venous BLL obtained

›Oral chelation not required

›Clear source identification and removal plan

›Environmental assessment arranged

08Treatment/t83

Source removal

›Source identification and elimination

›Single most important intervention

›BLL will not decline without source removal

›Chelation is adjunctive to elimination

›Environmental lead hazard abatement

›Lead paint encapsulation or removal by certified contractor

›Lead pipe replacement or filtration for water

›Occupational removal

›Work removal until BLL below occupational threshold

›Decontamination procedures for take-home exposure

›Whole bowel irrigation for GI lead

›Polyethylene glycol 25 to 40 ml/kg per hour up to 2 L per hour in adults

›Continue until rectal effluent clear and KUB shows clearance

›Indicated when radiopaque material visible on KUB

Chelation therapy: oral agents

›Succimer (DMSA)

›Indications

›Children with BLL >= 45 micrograms per dL

›First-line oral chelator for children

›Adults with BLL >= 40 micrograms per dL and symptomatic

›Dosing in children

›1050 mg per m2 per day in 3 divided doses for first 5 days

›Then 700 mg per m2 per day in 2 divided doses for 14 days

›Total course 19 days

›Monitoring during succimer

›LFTs and CBC at baseline and during treatment

›Rash and hypersensitivity monitoring

›BLL rebound after course: repeat in 2 weeks

›D-Penicillamine

›Indications

›Mild to moderate cases when other agents unavailable

›Less commonly used alternative oral chelator

›Considerations

›Higher side effect profile than succimer

›Hypersensitivity in penicillin-allergic patients

Chelation therapy: parenteral agents

›CaNa2EDTA (edetate calcium disodium)

›Indications

›BLL 20 to 70 micrograms per dL: may use alone

›BLL > 70 micrograms per dL: must combine with dimercaprol (BAL)

›CaNa2EDTA alone contraindicated at BLL > 70 as may aggravate symptoms

›Dosing

›1000 mg per m2 per day IV or IM for 5 days

›Maximum 1500 mg per day in adults

›Renal precautions

›Ensure urine output before initiating

›Dose reduce in renal impairment

›Hold if anuria or oliguria develops

›Monitor BUN and creatinine daily during treatment

›Dimercaprol (BAL)

›Indications

›BLL >= 70 micrograms per dL or encephalopathy

›Always combined with CaNa2EDTA for severe poisoning

›Dosing

›75 mg per m2 IM every 4 hours for 5 days

›Start CaNa2EDTA 4 hours after first BAL dose

›BAL-specific precautions

›Peanut oil vehicle: peanut allergy contraindication

›Hepatotoxicity monitoring

›Fever and nausea common side effects

›IM route only

Supportive care

›Nutritional interventions

›Iron supplementation when iron deficient

›Iron deficiency enhances lead absorption

›Ferrous sulfate 3 mg per kg per day elemental iron in children

›Calcium-rich diet

›Dairy intake associated with lower BLL

›Competes with lead for intestinal absorption

›Avoid fasting in children

›Empty stomach increases lead absorption

›Vitamin C intake may reduce absorption

›Seizure management

›Benzodiazepines first line for acute seizures

›Lorazepam 0.1 mg per kg IV in children, up to 4 mg

›Lorazepam 2 to 4 mg IV in adults

›Phenytoin or levetiracetam for recurrent seizures

›Levetiracetam 20 to 60 mg per kg IV loading dose in children

›Phenytoin 15 to 20 mg per kg IV in adults

›Cerebral edema management if encephalopathy

›Head of bed 30 degrees elevation

›Reduce intracranial pressure

›Avoid excessive IV fluids

›Mannitol 0.5 to 1 g per kg IV if herniation signs

›Neurosurgery consult for refractory ICP elevation

›Avoid in anuria

09Special Populations/sp83

Pregnancy

›Pregnancy-specific considerations

›Lead remobilization from bone stores during pregnancy

›Calcium homeostasis changes release stored lead

›Also occurs during lactation and menopause

›Fetal neurotoxicity risk

›Lead crosses the placenta freely

›No safe BLL threshold for fetal neurodevelopment

›ACOG recommends screening for elevated BLL in pregnant women

›Committee Opinion No. 533 guidance

›Screen women with risk factors

›Management in pregnancy

›Source removal as primary intervention

›Environmental lead hazard remediation before delivery

›Occupational removal

›Chelation in pregnancy

›Generally avoided unless severe maternal toxicity (encephalopathy)

›Succimer safety in pregnancy not established

›Benefit-risk discussion with toxicology

›Monitoring

›BLL at first prenatal visit if risk factors present

›Fetal monitoring when BLL elevated

›Nutritional calcium supplementation to reduce lead mobilization

›Breastfeeding

›Lead transfers into breast milk

›BLL > 40 micrograms per dL: breastfeeding generally avoided

›BLL 5 to 40 micrograms per dL: individual risk-benefit decision

Geriatric

›Older adult-specific risks

›Bone lead remobilization

›Osteoporosis and bone remodeling release stored lead

›Historical occupational or environmental exposure may re-emerge

›Cardiovascular risk amplification

›Lead-attributable cardiovascular disease burden established by GBD 2026 analysis

›Hypertension and chronic kidney disease interaction

›Saturnine gout prevalence higher in older adults

›Lead nephropathy accumulated over decades

›Allopurinol caution with renal impairment

›Management modifications

›Chelation caution in renal impairment

›CaNa2EDTA dose reduction required

›Nephrology co-management recommended

›Cardiovascular monitoring

›QTc monitoring during chelation

›AV block risk higher in older patients

›Cognitive assessment at baseline

›Pre-existing cognitive impairment may confound lead encephalopathy diagnosis

›Collateral history from caregivers essential

Pediatrics

›Why children are uniquely vulnerable

›Higher GI absorption rate

›Children absorb 40 to 50 percent of ingested lead vs 10 percent in adults

›Enhanced by iron or calcium deficiency

›Mouthing behaviors

›Age < 6 years highest risk

›Hand-to-mouth contact with lead dust

›Developing central nervous system

›No safe BLL threshold for neurocognitive effects

›Effects may be irreversible: chelation does not reverse neurocognitive damage

›Pediatric-specific presentations

›Behavioral and developmental manifestations at low BLL

›ADHD-like symptoms

›Learning disabilities

›Reduced IQ points per microgram per dL increment

›Classic acute presentations

›New-onset seizures with developmental regression

›Acute behavioral changes and lethargy

›Persistent vomiting and ataxia

›Pediatric treatment modifications

›Succimer weight-based dosing

›1050 mg per m2 per day for first 5 days

›700 mg per m2 per day for subsequent 14 days

›CaNa2EDTA pediatric dosing

›1000 mg per m2 per day IV or IM for 5 days

›Maximum 1500 mg per day

›Developmental monitoring mandate

›Referral for neurodevelopmental assessment with any elevated BLL

›Early intervention services for affected children

›School-age neurocognitive testing

›Screening protocol

›Universal screening in high-risk populations

›USPSTF recommends screening children at 1 and 2 years in high-risk areas

›Medicaid requires screening at 12 and 24 months

›Sibling screening

›All household contacts of index case

›Same exposure source likely

10Background/b85

Epidemiology

›Global and US burden

›Lead the most prevalent heavy metal toxin worldwide

›GBD 2026 data: lead-attributable cardiovascular disease a major cause of premature death

›800 million children estimated to have elevated BLL globally

›US prevalence

›CDC 2021 updated reference value of 3.5 micrograms per dL in children

›Significant racial and socioeconomic disparities

›Non-Hispanic Black children have higher prevalence of elevated BLL

›High-risk populations and exposure disparities

›Children under age 6

›Higher GI absorption rate

›Mouthing behaviors increase ingestion

›Low socioeconomic status households

›Older housing stock with lead paint

›Lead service lines for drinking water

›Occupational exposure groups

›Battery manufacturing and recycling workers

›Construction and demolition workers

›Radiator repair workers

›Geographic clustering

›Proximity to smelters and industrial sites

›Airports with leaded aviation fuel

›Flint Michigan water crisis as modern paradigm

Pathophysiology

›Lead absorption and distribution

›Routes of entry

›Ingestion primary in children

›Inhalation primary in occupational settings

›Dermal absorption minimal

›Bone compartment

›95 percent of lead stored in bone in adults

›Redistribution during pregnancy, menopause, or hyperthyroidism

›Half-life in bone 10 to 30 years

›Mechanisms of toxicity

›Heme synthesis disruption

›Inhibits delta-aminolevulinic acid dehydratase

›Inhibits ferrochelatase

›Results in microcytic hypochromic anemia and ZPP elevation

›Neurological toxicity

›Interferes with calcium-dependent neuronal signaling

›Disrupts N-methyl-D-aspartate receptor function

›Impairs synaptic transmission and myelination

›Oxidative stress in CNS

›Renal toxicity

›Proximal tubular cell injury

›Lead inclusion bodies in tubular nuclei

›Saturnine gout from urate retention

›Cardiovascular effects

›Vascular smooth muscle contraction and hypertension

›QTc and QRS prolongation at cumulative exposure

›10 microgram per gram increase in tibia lead associated with 5 ms increase in QTc

›Developmental neurotoxicity mechanism

›No safe threshold for children

›Dose-dependent IQ reduction at any BLL above background

›Affects hippocampal development and executive function

›Irreversibility

›Chelation reduces BLL but does not reverse neurocognitive damage already done

›Prevention and early exposure elimination are critical

Therapeutic Considerations

›Chelation principles

›Mechanism of chelation

›Chelating agents form stable water-soluble complexes with lead

›Urinary excretion of lead-chelator complex

›BLL rebound after chelation from bone redistribution

›Treatment goal hierarchy

›Source removal is primary: chelation cannot compensate for ongoing exposure

›Chelation reduces circulating and soft tissue lead burden

›Serial courses may be needed for very high bone lead stores

›Evidence base for chelation thresholds

›Succimer trial evidence

›Randomized controlled trials show BLL reduction with succimer

›Neurocognitive outcomes not improved in trials of mildly elevated BLL children

›Most benefit from chelation at BLL >= 45 micrograms per dL

›Combination BAL plus CaNa2EDTA standard

›Supported by expert consensus for BLL >= 70 micrograms per dL

›BAL mobilizes intracellular lead for CaNa2EDTA to chelate

›Prevention as a therapeutic strategy

›Nutritional protection

›Calcium and iron compete with lead for intestinal absorption

›Vitamin C may have modest protective effect

›Environmental remediation evidence

›Household interventions reduce BLL in children: Cochrane 2020 review supports

›Lead paint encapsulation combined with cleaning most effective

›Public health approach

›Universal screening in high-risk populations

›Mandatory reporting facilitates case identification and source investigation

›Primary prevention through infrastructure replacement (lead pipes)

11Patient Discharge Instructions/pdi43

copy discharge instructions

›Lead poisoning home care

›Diagnosis explanation

›Lead is a toxic metal that causes harm to the brain, blood, kidneys, and nerves

›Even small amounts can be harmful especially in children

›The most important step is finding and stopping the source of lead

›Medications as prescribed

›Take all chelation medication exactly as directed

›Do not stop early even if feeling better

›If taking succimer, take with food if stomach upset occurs

›Diet recommendations

›Calcium-rich foods daily: milk, yogurt, cheese

›Iron-rich foods: meat, beans, fortified cereals

›Do not give on an empty stomach: full stomach slows lead absorption

›Avoid fasting especially in young children

›Exposure prevention at home

›Lead paint

›Do not let children chew or mouth painted surfaces in older homes

›Wet mop and wet wipe rather than dry sweep to control lead dust

›Contact local health department for free lead paint assessment

›Water

›Run cold water for 30 seconds to 2 minutes before using if pipes are old

›Use a certified lead-removing water filter

›Never use hot tap water for cooking or infant formula

›Hand hygiene

›Wash hands before eating especially after outdoor play

›Remove shoes at the door to reduce tracked-in lead soil

›Toys and objects

12References/r27

Guidelines and key sources

›Primary references

›Lanphear B, Navas-Acien A, Bellinger DC. Lead Poisoning. New England Journal of Medicine. 2024

›Comprehensive review of sources, health effects, and management

›NEJM 2024: https://www.nejm.org/doi/full/10.1056/NEJMra2402527

›CDC Childhood Lead Poisoning Prevention Training 2023 to 2024

›BLL reference value updated to 3.5 micrograms per dL (2021 MMWR)

›Ruckart PZ et al. MMWR 2021

›USPSTF Recommendation Statement: Screening for Elevated Blood Lead Levels in Children and Pregnant Women. JAMA 2019

›Curry SJ, Krist AH et al. JAMA 2019

›Epidemiology and cardiovascular burden

›GBD 2023 Lead Collaborators. Lead-Attributable Cardiovascular Disease Burden. JAMA 2026

›Stanaway JD, Spearman S et al.

›Establishes global cardiovascular mortality attributable to lead

›Miller MR, Landrigan PJ, Arora M et al. Water, Soil, Noise, and Light Pollution. JACC 2024

›Chelation and treatment evidence

›Samarghandian S et al. Systematic Review of Clinical and Laboratory Findings of Lead Poisoning. Toxicology and Applied Pharmacology. 2021

›Nussbaumer-Streit B et al. Household Interventions for Secondary Prevention of Domestic Lead Exposure in Children. Cochrane Database of Systematic Reviews. 2020

›Committee on Obstetric Practice. ACOG Committee Opinion No. 533: Lead Screening During Pregnancy and Lactation. Obstetrics and Gynecology. 2012

Electrocardiographic and imaging references

›ECG studies

›Eum KD, Nie LH, Schwartz J et al. Lead Exposure and ECG Conduction Disturbances. Environmental Health Perspectives. 2011

›Kieltucki J, Dobrakowski M, Pawlas N et al. QT Interval and Lead Exposure. Human and Experimental Toxicology. 2017

›10 microgram per gram tibia lead associated with approximately 5 ms QTc prolongation

›Radiological references

›Alvarenga Fernandes D et al. Radiological Changes in Lead Poisoning. Clinical Toxicology. 2024

›McElvaine MD et al. Prevalence of Radiographic Evidence of Paint Chip Ingestion. Pediatrics. 1992

›26 percent of children with BLL >= 55 micrograms per dL had positive KUB

Evidence & Review